Physician Perspectives 2017: Biosimilar use in IBD

Physician Perspectives 2017: Biosimilar use in IBD

  • Products Id :- GDHC002SP
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Physician Perspectives 2017: Biosimilar use in IBD


This Physician Perspectives survey focuses on the use of biosimilar anti-TNFs in IBD.

In the next 12 months, nearly half of physicians stated that they would consider switching Remicade patients (in remission) over to biosimilar IFX. A large proportion of physicians reported that their patients have at least occasionally expressed concern (rated >3) over being switched onto a biosimilar anti-TNF from an originator anti-TNF (67%) or being prescribed a biosimilar anti-TNF (54%). Overall, the majority of physicians agreed that they would require a biosimilar to be designated as interchangeable before considering switching patients from an originator to a biosimilar (67%).

The report includes following topics-

- Familiarity with biosimilar IFX

- Expected use of biosimilars-IFX & ADA

- Concerns with biosimilars

- Switching & Interchangeability.


- Sociable Pharma conducted an online survey in Q4 2017, with 100 specialist gastroenterologists

- Physicians interviewed were from 5EU and US countries This report contains the findings from the survey, together with analysis, as well as an overview of the methodology used, and responder demographics.

Reasons to buy

- Qualitative insight from 100 high-prescribing specialists in IBD

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of contents

Executive Summary


Survey Results



Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]




Biosimilars, IBD, interchangeability

select a license
Single User License
USD 2500 INR 171550
Site License
USD 5000 INR 343100
Corporate User License
USD 7500 INR 514650



The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]